Oncogenic signals as treatment targets in classic myeloproliferative neoplasms

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Myeloproliferative neoplasms (MPNs) are a group of blood cancers characterized by the overproduction of myeloid cells.
• Therapeutically validated oncoproteins, including BCR-ABL in chronic myelogenous leukemia (CML), are crucial in MPN pathogenesis.
• Other MPN-associated oncogenes like JAK2, MPL, KIT, and FGFR1 require further therapeutic validation.

Purpose of the Study:

• To review mutant molecules implicated in classic MPNs (CML, polycythemia vera, essential thrombocythemia, primary myelofibrosis).
• To evaluate the therapeutic potential of these mutant molecules as drug targets.

Main Methods:

• Literature review of studies on MPN-associated oncoproteins.
• Analysis of the role of specific mutations and gene fusions in MPN development.
• Assessment of current and potential therapeutic strategies targeting these oncogenes.

Main Results:

• BCR-ABL oncoprotein is a validated target in CML.
• Mutations in JAK2, MPL, KIT, and FGFR1 are key drivers in other MPNs and represent promising therapeutic targets.
• Gene fusions involving PDGFRA/B, such as FIP1L1-PDGFRA and ETV6-PDGFRB, are also important targets.

Conclusions:

• Targeting specific oncoproteins offers a promising therapeutic strategy for MPNs.
• Further research into validating novel drug targets is essential for improving patient outcomes in MPNs.
• Understanding the molecular basis of MPNs is critical for developing effective treatments.